<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02491788</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-34778</org_study_id>
    <nct_id>NCT02491788</nct_id>
  </id_info>
  <brief_title>Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Palo Alto Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Palo Alto Health Care System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting
      drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight
      shifts will significantly improve both objective (total sleep time, sleep efficiency, wake
      after sleep onset) and subjective (sleep quality) measures of daytime sleep.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Total Sleep Time</measure>
    <time_frame>Daytime sleep will be examined over three weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Sleep Disorder, Shift-Work</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg of suvorexant 30 minutes prior to daytime sleep opportunity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill 30 minutes prior to daytime sleep opportunity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <arm_group_label>Drug</arm_group_label>
    <other_name>Belsomra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 20-60 (older individuals excluded due to altered sleep-related circadian
             signaling)

          -  Males and females

          -  Shift worker

               -  Minimum of three months of prior shift work

               -  Will work minimum of four nights per week or 32 hours of night shift per week
                  during study

               -  &quot;Night work&quot; defined as having at least six hours of work occurring between 8 PM
                  and 8 AM and no longer than 12 hours on shift

          -  Presence of DSM-5 defined Circadian Rhythm Sleep-Wake Disorder: Shift Work Type

               -  Insomnia (SE &lt; 88%) during attempted daytime sleep or excessive sleepiness during
                  nocturnal wake

        Exclusion Criteria:

          -  Currently or planning to become pregnant

          -  Currently breastfeeding

          -  Inadequate opportunity (&lt;7 hours) for daytime sleep after shift work

          -  Use of sleep aids during the study period. Includes as needed or continuous use of
             prescription, non-prescription, and naturopathic pharmacotherapies

          -  Diagnosis or detection (during study) of sleep disordered breathing (AHI&gt;10) on home
             sleep testing; referral to clinical sleep program will be offered

          -  Diagnosis of narcolepsy

          -  Restless Legs Syndrome

          -  &gt;600 mg caffeine intake per night shift or use of prescription stimulant medication
             during night shift

          -  Rotational or irregular work shifts during study

          -  Use of digoxin for six months prior to or during study

          -  Use of strong (e.g., etoconazole, itraconazole, posaconazole, clarithromycin,
             nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir,
             telithromycin, conivaptan) or moderate (e.g., amprenavir, aprepitant, atazanavir,
             ciprofloxacin, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice,
             imatinib, verapamil) CYP3A inhibitors or CYP3A inducers (e.g., rifampin,
             carbamazepine, phenytoin) for six months prior to or during study

          -  Severe hepatic impairment

          -  Unstable or severe medical or psychiatric condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yvonne Quevedo</last_name>
    <phone>650-493-5000</phone>
    <phone_ext>61971</phone_ext>
    <email>pavasleepstudy@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Quevedo</last_name>
      <email>yvonne.quevedo@va.gov</email>
    </contact>
    <investigator>
      <last_name>Jamie M Zeitzer, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Palo Alto Health Care System</investigator_affiliation>
    <investigator_full_name>Jamie M. Zeitzer, Ph.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Sleep Disorders, Circadian Rhythm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All relevant data will be provided in the publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

